AQX-MN100 is the company's most advanced product and is being developed for the treatment of cancer and inflammatory disease. It has many desirable drug attributes that make it especially compelling:

• it is highly selective


• it is a small molecule (<500 daltons)


• it is cell permeable


• it is easily synthesized


• it is orally bioavailable


• it has shown potent anti-cancer activity as well as anti-inflammatory activity both in vitro and in vivo